europathic Pain in Ankylosing Spondylitis: Association with Functional Status, Quality of Life, Sleep Quality, Disease Activity, and Depression Levels
Not Applicable
Recruiting
- Conditions
- Musculoskeletal DiseasesOrthopaedics
- Registration Number
- PACTR202401754503987
- Lead Sponsor
- Faculty of Medicine Al Azhar University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
Consecutive patients >18 years
- Consecutive patients <65 years
- Classified with Ankylosing Spondylitis according to the New York classification criteria
- Patients agreed to participate in the study
Exclusion Criteria
- Patients who were pregnant;
- Patients with any rheumatological disease other than Ankylosing Spondylitis
- Patients diagnosed with fibromyalgia or other systemic diseases affecting sleep quality
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie neuropathic pain in ankylosing spondylitis patients with axial involvement?
How does neuropathic pain in ankylosing spondylitis compare to standard-of-care treatments like TNF inhibitors in terms of functional improvement?
Are there specific biomarkers such as cytokine profiles or nerve growth factors that predict neuropathic pain severity in ankylosing spondylitis?
What adverse events are commonly associated with neuropathic pain management in ankylosing spondylitis and how are they managed?
What combination therapies involving IL-17 or IL-23 inhibitors show promise in treating neuropathic pain in ankylosing spondylitis?